Trial abstract · §3
REIMAGINE-1 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Safety, tolerability and pharmacokinetics of ascending subcutaneous and oral doses, with percentage change in body weight as an exploratory endpoint | Exploratory weight reduction of approximately 13 % at 12 weeks with the subcutaneous presentation. The Institute treats an exploratory endpoint in a phase 1 study as hypothesis-generating and grades every amycretin efficacy claim very low certainty on that ground | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Amycretin from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | — | — | Class-typical; not fully tabulated at phase 1b |
| Vomiting | — | — | Reported |
| Discontinuation for adverse events | — | — | Not fully tabulated |
Compound Evidence Institute · CEI-TR-0135/3 · https://compoundevidence.com/trials/reimagine-1/results/ · retrieved 30 July 2026